Last: | $13.10 |
---|---|
Change Percent: | -0.98% |
Open: | $13.15 |
Close: | $13.23 |
High: | $13.19 |
Low: | $13.07 |
Volume: | 1,018,651 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$13.1 | $13.15 | $13.23 | $13.19 | $13.07 | 1,018,651 | 04-25-2024 |
$13.23 | $13.32 | $13.23 | $13.33 | $13.21 | 924,523 | 04-24-2024 |
$13.38 | $13.37 | $13.38 | $13.41 | $13.3 | 1,702,435 | 04-23-2024 |
$13.36 | $13.31 | $13.36 | $13.41 | $13.295 | 1,561,448 | 04-22-2024 |
$13.24 | $13.18 | $13.24 | $13.26 | $13.17 | 1,316,677 | 04-19-2024 |
$13.16 | $13.16 | $13.16 | $13.225 | $13.12 | 1,287,745 | 04-18-2024 |
$13.15 | $13.18 | $13.15 | $13.18 | $13.11 | 1,639,877 | 04-17-2024 |
$13.23 | $13.22 | $13.23 | $13.3 | $13.22 | 2,279,140 | 04-16-2024 |
$13.18 | $13.31 | $13.18 | $13.345 | $13.17 | 1,788,861 | 04-15-2024 |
$13.37 | $13.51 | $13.37 | $13.56 | $13.35 | 2,244,598 | 04-12-2024 |
$13.58 | $13.49 | $13.58 | $13.6 | $13.465 | 3,030,911 | 04-11-2024 |
$13.57 | $13.5 | $13.57 | $13.59 | $13.455 | 2,418,988 | 04-10-2024 |
$13.65 | $13.67 | $13.65 | $13.69 | $13.59 | 1,432,021 | 04-09-2024 |
$13.67 | $13.63 | $13.67 | $13.775 | $13.62 | 2,064,229 | 04-08-2024 |
$13.62 | $13.52 | $13.62 | $13.62 | $13.44 | 1,822,690 | 04-05-2024 |
$13.48 | $13.55 | $13.48 | $13.61 | $13.46 | 1,783,275 | 04-04-2024 |
$13.53 | $13.51 | $13.53 | $13.58 | $13.465 | 1,760,155 | 04-03-2024 |
$13.55 | $13.58 | $13.55 | $13.6 | $13.48 | 1,856,058 | 04-02-2024 |
$13.67 | $13.78 | $13.67 | $13.78 | $13.62 | 1,158,879 | 04-01-2024 |
$13.89 | $13.94 | $13.89 | $13.96 | $13.82 | 1,484,704 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAVITRI ™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MA...
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK...